English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Endovascular aneurysm repair (EVAR) is associated with increased re-intervention rates compared to open repair (OR). EVAR patients are exposed to more radiation, with an incremental increased risk of cancer development. We aim to quantify re-intervention rates and metachronous malignancies following EVAR or OR. Methods: From 2004–2019, 1016 patients underwent aneurysm repair (868: EVAR, 148: OR). Computerized tomography (CT) and X-ray radiation doses and intraoperative EVAR radiation exposure were analyzed. Reintervention rates were stratified according to procedure and device used. Results: Demographics and vascular related risk factors were similar in EVAR and OR. EVAR patients were exposed to an average of 1.09 follow-up CT scans and 1.7 plain film abdomen X-ray (PFA) during follow-up, compared to 0.2 CT scans and 0.52 PFA in OR. The percentage of EVAR patients requiring endovascular re-intervention was 6.2% vs. 2.7% OR patients. The number of re-interventions per graft were 9/183 Gore grafts, 10/62 Cordis, 52/277 Endurant, 26/77 Talent, 13/143 Endologix and 3/4 Cook grafts. The number of endoleaks developed post EVAR were 35/868, with twelve delayed open conversions. Of the open Repairs, 4/148 ORs required repair of an incisional hernia. EVAR patients developed a metachronous malignancy at 8.5% (74/868) compared to 4% (6/148) OR patients. The number of malignancies per graft were 16/183 Gore patients, 6/62 Cordis, 32/277 Endurant, 0/77 Talent and 20/143 Endologix patients developed malignancies. At 10-year, malignancy-related survival was 96.2% in EVAR patients compared to 96.4% in OR. All-cause survival was 70.8% in EVARs vs. 66.1%in OR. More patients died in both groups from cardiovascular related causes rather than malignancy. Conclusions: EVAR is associated with increased incidence of metachronous malignancy, but does not influence malignancy-related deaths.

AB040. Re-intervention and malignancy development post-endovascular aneurysm repair—fifteen-year experience of aneurysm repair